A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients

NCT03849768 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

429

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: HS-10296
DRUG: Gefitinib

Sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd.